Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/OTT.S46545 http://scihub22266oqcxt.onion/10.2147/OTT.S46545 C3787923!3787923!24092989     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Onco+Targets+Ther 2013 ; 6 (ä): 1231-41 Nephropedia Template TP {{tp|p=24092989|t=2013. The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer |pdf=|usr=}}{{24092989}} gab.com Text The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer JO: Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=24092989 #FOAvip Anaplastic thyroid cancer represents 1%?2% of thyroid cancers. For its aggressiveness, it is considered a systemic disease at the time of diagnosis. Surgery remains the cornerstone of therapy in resectable tumor. Traditional chemotherapy has little effect on metastatic disease. A multimodality approach, incorporating cytoreductive surgical resection, chemoradiation, either concurrently or sequentially, and new promising target therapies is advisable. Doxorubicin is the most commonly used agent, with a response rate of 22%. Recently, other chemotherapy agents have been used, such as paclitaxel and gemcitabine, with superimposable activity and response rates of 10%?20%. However, survival of patients with anaplastic thyroid cancer has changed little in the past 50 years, despite more aggressive systemic and radiotherapies. Several new agents are currently under investigation. Some of them, such as sorafenib, imatinib, and axitinib have been tested in small clinical trials, showing promising disease control rates ranging from 35%?75%. Referral of patients for participation in clinical trials is needed. Twit Text FOAVip The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer ????Onco Targets Ther http://www.kidney.de/pget.php?&tw=1&pmid=24092989 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24092989 #FOAvip English Wikipedia <ref>{{Cite pmid|24092989}}</ref> The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer #MMPMID24092989 Denaro N; Nigro CL; Russi EG; Merlano MC Onco Targets Ther 2013[]; 6 (ä): 1231-41 PMID24092989show ga Anaplastic thyroid cancer represents 1%?2% of thyroid cancers. For its aggressiveness, it is considered a systemic disease at the time of diagnosis. Surgery remains the cornerstone of therapy in resectable tumor. Traditional chemotherapy has little effect on metastatic disease. A multimodality approach, incorporating cytoreductive surgical resection, chemoradiation, either concurrently or sequentially, and new promising target therapies is advisable. Doxorubicin is the most commonly used agent, with a response rate of 22%. Recently, other chemotherapy agents have been used, such as paclitaxel and gemcitabine, with superimposable activity and response rates of 10%?20%. However, survival of patients with anaplastic thyroid cancer has changed little in the past 50 years, despite more aggressive systemic and radiotherapies. Several new agents are currently under investigation. Some of them, such as sorafenib, imatinib, and axitinib have been tested in small clinical trials, showing promising disease control rates ranging from 35%?75%. Referral of patients for participation in clinical trials is needed. äThe role of chemotherapy and latest emerging target therapies in anapl(epmc).pdf DeepDyve Pubget Overpricing